The Supreme Court has refused to consider Eli Lilly and Takeda’s contention that a racketeering lawsuit against the pharma companies shouldn’t proceed as a class action. The lawsuit accuses the companies of violating the Racketeer Influenced and Corrupt Organizations Act by marketing the Actos diabetes drug without disclosing its link to bladder cancer. The case covers tens of thousands of insurers and other third-party payers that reimbursed the cost of five or more separate Actos prescriptions.